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Inflammatory eye disease: pre-treatment assessment of patients prior to 
commencing immunosuppressive and biologic therapy: 
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Abstract 
 
Aim 
To outline recommendations from an expert committee on the assessment 
and investigation of patients with severe inflammatory eye disease commenc-
ing immunosuppressive and/or biologic therapy. 
 
Method 
The approach to assessment is based on the clinical experience of an expert 
committee and a review of the literature with regard to corticosteroids, immu-
nosuppressive drug and biologic therapy and other adjunct therapy in the 
management of patients with severe sight-threatening inflammatory eye dis-
ease. 
 
Conclusion 
We recommend a careful assessment and consultative approach by ophthal-
mologists or physicians experienced in the use of immunosuppressive agents 
for all patients commencing immunosuppressive and/or biologic therapy for 
sight threatening inflammatory eye disease with the aim of preventing infec-
tion, cardiovascular, metabolic and bone disease and reducing iatrogenic side 
effects.  
 
 
Introduction 
 
Inflammatory eye diseases (IED), such as uveitis and scleritis, are a signifi-
cant cause of blindness and visual impairment worldwide[1-5]. Although corti-
costeroids remain the mainstay of initial therapy and are effective in the rapid 
control of IED, the common occurrence of significant side effects related to 
prolonged systemic corticosteroid therapy and the loss of disease control as 
the steroid dose is decreased, often necessitates the use of additional immu-
nosuppressive agents[6]. In addition, a proportion of patients have severe 
ocular disease that is resistant to corticosteroid therapy[7, 8]. The drugs most 
commonly used as corticosteroid-sparing agents include : azathioprine, me-
thotrexate, mycophenolate and cyclosporine, whilst tacrolimus and cyclo-
phosphamide are used infrequently[8]. All these drugs are associated with the 
potential for significant side effects and important drug interactions[9]. Recent-
ly, biologic agents, including antibodies against cytokines, such as tumor ne-
crosis factor-α, IL-1β, IL-6, anti B (anti-CD20) and T cell antibodies like IL-2R, 
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as well as the cytokine IFN-α have become available to treat patients with 
uveitis and other inflammatory eye diseases[10, 11]. 
 
The aims of immunosuppressive therapy in patients with IED include: the pre-
servation and/or recovery of vision, relief of associated symptoms, and main-
tenance of the patient’s quality of life. Importantly, this should lead to the pre-
vention of complications of their underlying disease combined with prevention 
of drug-related adverse events and complications, particularly those from un-
necessary high maintenance doses of (>7.5 mg/day) corticosteroid therapy[6, 
12].   
An essential component in achieving these aims is a careful and considered 
assessment and planning process. Such an assessment would normally be 
carried out in parallel with investigations into the etiology of the patient’s in-
flammatory eye disease and typically after the commencement of high dose 
systemic corticosteroid therapy, as the majority of patients present with acute 
vision-threatening inflammation that requires urgent therapy. There are pre-
vious publications and reports of the evaluation and assessment of patients 
before starting immunosuppressive or biological therapy, although there have 
been no systematic reviews or expert guidelines developed for patients with 
IED[8, 13]. 
 
The primary objective of these recommendations is to assist ophthalmologists 
and physicians caring for patients with IED and provide a framework to help 
guide baseline information gathering about patients prior to commencing sys-
temic immunosuppressive therapy. These recommendations are summarized 
in Table 1 and are designed for physicians and members of the clinical team 
caring for patients with IED who require systemic immunosuppressive and/or 
biologic therapy and are not meant to be prescriptive or essential in all cases. 
It is the responsibility of the treating ophthalmologist or internist to decide on 
the appropriate investigations for the individual patient, and such considera-
tions will be based on experience, socioeconomic and geographical consider-
ations, as well as availability of tests and cost. 
 
Methodology 
A 12-person panel of physicians and scientists with expertise in ophthalmolo-
gy, pediatrics, infectious disease, rheumatologic disease, research, and the 
use of immunosuppressive drugs in patients with IED, drafted the initial rec-
ommendations, which were subsequently reviewed by members of an ex-
tended panel.  
 
Evidence 
Published clinical study results and adopted recommendations from other ex-
pert bodies, including the American College of Rheumatology [14](ACR) and 
Centre for Disease Control (CDC), where relevant. Recommendations were 
rated according to the quality and strength of available evidence and relevant 
guidelines developed by other expert committees. 
Process 
The panel was convened in September 2015 and communicated regularly 
through March 2016. Subgroups of the panel summarized and presented 
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available information on specific topics to the full panel; recommendations and 
ratings were determined by group consensus. 
 
Recommendations 
 
 
Recommendation 1. 
Prior to immunosuppressive or biologic therapy, patients should have a 
comprehensive and individualized pre-treatment evaluation (Table 2) to 
prevent or minimize therapy and disease-related complications. 
 
The pre-treatment evaluation of patients with IED is instituted at the time of 
diagnosis in parallel with diagnostic evaluation and prior to commencing im-
munosuppressive (IS) therapy. The aims of this pre-treatment evaluation are 
to establish a baseline of vital organ function; ensure there are no associated 
systemic inflammatory, malignant, infective, gastrointestinal or psychological 
disorders that may be reactivated or exacerbated by IS therapy; and evaluate 
the patient’s risk for drug interaction and potential severe treatment-limiting 
side effects. 
 
Table 2 summarizes an approach to the pre-treatment evaluation of patients 
with IED prior to commencing systemic IS therapy. It outlines the important 
considerations, relevant features and investigations to be considered based 
on a careful clinical assessment. The table is not meant to be comprehensive 
or to replace good clinical judgment but is intended to serve as a guide to en-
sure due consideration is given to relevant and important aspects of the man-
agement of patients requiring systemic immunosuppressive therapy. The ta-
ble does not relate to the investigation of patients required to establish an un-
derlying cause for the IED, particularly infectious causes of IED. The devel-
opment of suitable questionnaires may facilitate the pre-treatment assess-
ment of patients with IED. 
 
Infections that may be exacerbated or reactivated as a result of systemic im-
munosuppressive of biological therapy include: TB, HBV, HCV and HIV. 
These infection risks should be assessed or excluded before commencing 
such therapy. Infections, such as TB, require therapy to allow safe use of IS 
therapy[13, 15, 16]. The patient’s immune status and immunization history are 
important in planning on-going prevention of infection whilst on immunosup-
pressive therapy (see recommendation 4).  
 
As most immunosuppressive drugs have the potential to cause or exacerbate 
hematological problems, it is essential to perform a baseline blood count, in-
cluding red and white blood cells and platelet counts. Similarly, as most IS 
drugs are metabolized and/or secreted by the liver and/or kidney, it is essen-
tial to ensure there is normal hepatorenal function before commencing such 
therapy. These organs may also be adversely affected by IS medications, par-
ticularly cyclosporine and it is important to measure baseline and on-going or-
gan function during the course of treatment. 
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Most treatment regimens include chronic use of low dose corticosteroids af-
fecting bone density[17]. Therefore bone densitometry and appropriate sup-
plement with vitamin D and calcium are important considerations to avoid 
subsequent morbidity[18] (see recommendation 3).  Dietary advice is appro-
priate for patients with diabetes and obesity and patients with a history of ga-
stro esophageal reflux or peptic ulcer disease may benefit from treatment with 
a proton pump inhibitor. 
 
Evaluating cardiovascular risk factors and endocrine status (e.g. hyperten-
sion, obesity, diabetes and thyroid disease) are important as chronic corticos-
teroid use may also lead to elevation of total cholesterol, glucose intolerance, 
increased blood pressure and weight gain. Assessment of cardiovascular risk 
factors in patients with associated systemic disorders, such as systemic lupus 
erythematosus and rheumatoid arthritis, is especially vital as they are asso-
ciated with endothelial cell dysfunction and unregulated pro-inflammatory cy-
tokines, resulting in accelerated risk of atherosclerosis and its 
complications[19].  
 
As an integral part of the initial assessment of the patient, it is important to 
consider pre-existing or recent malignancy or pre-malignant lesions that may 
be exacerbated by IS therapy[20]. Although a long term study did not reveal 
an increased rate of death related malignancies in patients on long term IS 
therapy for IED a recent study revealed that such patients have an increased 
risk of skin, cervical and lymphoid malignancies and patients should be 
screened for the presence of such neoplasms before commencing IS therapy 
[21, 22]. This is best achieved by a careful history, examination and targeted 
investigations. 
 
It is important to consider the presence of autoimmunity and/or autoantibodies 
for two reasons.  Firstly, certain autoimmune diseases may be associated with 
IED (e.g. rheumatoid arthritis (RA), systemic lupus erythematosus [23](SLE), 
ANCA-associated vasculitis (e.g. Granulomatous Polyangiitis, GPA etc.)) and; 
secondly, some biological agents, such as TNF inhibitors, rituximab and IFN-
alpha, may induce the production of autoantibodies[24]. TNF and IL-6 inhibi-
tors should be avoided in patients with a history of central demyelinating dis-
ease and should be used with great caution in patients carrying a risk for de-
myelination, such as patients with intermediate uveitis[25].  
 
Drug interactions are a critical factor in long-term systemic IS therapy and it is 
vital that this is evaluated both at the initial assessment and regularly during 
the patient’s treatment program. All IS drugs have significant potential for se-
rious drug interactions, especially when used in combination, and these are 
outlined in Table 3 for conventional immunosuppressants and in Table 4 for 
biologic agents[26]. 
 
The patient’s reproductive capacity and desire to have children should be dis-
cussed and evaluated, and potential drug side effects that may interfere with 
this function should be appraised[9, 27, 28]. This is mainly an issue in alkylat-
ing agent therapy, and consideration should be given to sperm or ovum bank-
ing. Such patients require referral to a specialist physician or gynecologist. 
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There are a number of other immunosuppressive drugs, such as methotrexate 
and mycophenolate, which are contraindicated in pregnant woman[28].  
 
 
Recommendation 2. 
An extended consultative approach to management of patients with as-
sociated systemic disease is recommended. 
 
The treatment of patients with severe uveitis is best managed by ophthalmol-
ogists experienced in the management of IED, in some circumstances this 
can be combined with the consultative input from internists experienced in the 
management of systemic inflammatory disorders and the use of immunosup-
pressive and biological drugs. Immunosuppressive therapy instituted to treat 
systemic disease will often control the associated uveitis [8, 11]. In other cas-
es, exacerbation of uveitis may be the first indication that the underlying sys-
temic disease is not under adequate control.  Experienced internists can con-
tribute significantly to the management of patients with chronic uveitis and 
other IED’s by detecting and treating malignancies or infections, which may 
produce a masquerade syndrome or complicate immunosuppressive therapy.  
 
The treatment of patients with IED has undergone significant change in recent 
times. These changes include: more aggressive and early treatment of pa-
tients with immunomodulatory therapy in order to maintain vision and achieve 
a rapid remission (e.g. in patients with Behcet’s disease); the introduction of 
new immunosuppressive agents that have significantly decreased morbidity; 
the increasing use of combination immunosuppressive therapy and biological 
agents in patients with severe and refractory ocular inflammatory disease 
(e.g. in children with JIA associated uveitis); and the increasing recognition of 
the potential paradoxical contribution of immunosuppressive therapy to the 
morbidity of certain inflammatory disease processes through the increased 
cardiovascular and oncogenic risks associated with their use[21, 29]. The de-
tection and management of such complications requires close collaboration 
between the treating ophthalmologist and other relevant specialist physicians. 
 
 
Recommendation 3. 
Patients treated with high-dose and prolonged systemic corticosteroids 
(>3 months) should have a baseline bone density and fracture risk as-
sessment, which should be repeated at regular intervals in patients on 
long term glucocorticoid therapy. Patients with evidence of significant 
bone loss and/or osteoporosis should have treatment to prevent further 
bone loss as early as possible after commencing corticosteroid therapy 
(Figure 1).  
 
It is important to measure baseline bone density in patients prior to or soon 
after the initiation of systemic corticosteroid therapy as up to 10% of bone 
mineral loss may occur in the first 3-6 months of systemic corticosteroid ther-
apy[30, 31]. Pre-existing osteoporosis should be treated to prevent worsening 
of this disease, as outlined below. Although the 54 month MUST study did not 
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reveal a high prevalence of osteoporosis in patients treated with systemic cor-
ticosteroids it is recommended that the management of osteoporosis or os-
teopenia in patients commenced on high-dose or prolonged corticosteroid 
therapy should be treated in accordance with established evidence based 
guidelines[32]. The American College of Rheumatology (ACR) has developed 
guidelines for the assessment, prevention and treatment of glucocorticoid-
induced osteoporosis[30, 32, 33]. These guidelines were developed by an ex-
pert committee and based on available evidence from the literature. As there 
has been no similar attempt to develop such guidelines for patients with IED, 
it is recommended that the ACR guidelines be used to help monitor and man-
age the risk of increased bone loss and osteoporosis. Measures should be 
implemented as early as possible to decrease the risk of bone loss in patients 
treated with corticosteroids. An increased risk of fracture has been reported 
with doses of prednisone or its equivalent as low as 2.5 to 7.5 mg daily[31]. 
Often, there are no clinical manifestations until there is a fracture. All patients 
taking any dose of corticosteroid with an anticipated duration of ≥3 months 
require an evaluation, which includes assessment of clinical risk factors for 
fracture, BMD (dual-energy x-ray [DEXA scan]) of the hip and spine, and 
measurement of serum 25-hydroxyvitamin D.  
 
Active measures should be employed to decrease bone loss. All patients 
should be encouraged to do weight-bearing exercises, avoid smoking, excess 
alcohol consumption and take positive measures to prevent falls (Table 5). 
Patients receiving any dose of chronic corticosteroid therapy or initiating corti-
costeroids with an anticipated duration of ≥3 months should take calcium 
(1200 mg daily), and vitamin D (800 IU daily)[30].  
 
It is recommended that men over 50 years and postmenopausal women, who 
are receiving or are about to commence systemic corticosteroid therapy (any 
dose for any duration), should receive osteoporosis treatment if one of the fol-
lowing criteria is fulfilled[30]:  
• having an established osteoporosis (T-score ≤-2.5 or history of fragility 
fracture) 
• bearing a risk to develop osteoporosis (T-scores between -1.0 and -
2.5) 
 
In centers in which FRAX measurement is available postmenopausal women 
and men over 50 years who have a low FRAX calculated absolute risk should 
receive appropriate therapy if they are taking ≥7.5 mg/day of prednisone or its 
equivalent for ≥3 months. This approach will vary between countries and rec-
ommendations and guidelines issued by different international groups and the 
availability of DEXA scans and FRAX measurement.  
Although estrogen replacement therapy has been demonstrated to prevent 
bone loss in postmenopausal women receiving systemic corticosteroid thera-
py, estrogen-progestin therapy is not recommended for the prevention or 
treatment of osteoporosis in postmenopausal women because of increased 
risk of breast cancer, stroke, venous thromboembolism and coronary artery 
disease[30].  
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Recommendation 4.  
Special considerations are essential in the pre-treatment assessment 
and management of children, pregnant women and older patients. 
 
Children 
Because of the potential risk of growth retardation in children treated with pro-
longed high-dose corticosteroids, they should have their height and weight 
recorded on a growth chart that should be kept up-to-date during therapy, by 
measuring these at each visit[34, 35].  
 
An increasing number of systemic drugs have been used to treat children with 
severe IED. These include: corticosteroids, methotrexate, azathioprine, my-
cophenolate, cyclosporine, sulfasalazine and TNF inhibitors. In contrast, cyc-
lophosphamide and other alkylating agents should be avoided in children. 
There is limited data for some of the newer biological agents and their use in 
children. The long-term effects on children exposed to these medications 
have not been extensively studied and such information will be invaluable in 
informing future therapy in this particular patient group. Appropriate immuniza-
tion to prevent infections in children is crucial to initial and long-term man-
agement and is discussed below[36]. 
 
Pregnant women  
A number of systemic drugs have been used to treat pregnant women with 
severe IED. These include: corticosteroids, azathioprine, cyclosporine, sulfa-
salazine, TNF inhibitors and interferons[28]. Methotrexate, cyclophosphamide, 
chlorambucil and mycophenolate should be avoided in pregnant women be-
cause of teratogenic issues[28]. There is limited data for some of the newer 
biological agents and their use in pregnancy. Non-steroidal anti-inflammatory 
drugs should be avoided in pregnant woman as they may result in the prema-
ture closure of the patent ductus arteriosus in the fetus.  
 
Women and men wishing to have children 
Men and women with childbearing potential should be counseled prior to 
treatment with cyclophosphamide, chlorambucil, methotrexate and mycophe-
nolate about the risk of infertility, and of premature menopause (primary ova-
rian insufficiency) in women[28]. Whenever possible, all patients should meet 
with a reproductive or infertility specialist prior to therapy with cyclophospha-
mide. Cryopreservation of semen is usually the preferred fertility-preserving 
measure in men. Women may be offered cryopreservation of embryos or oo-
cytes, although undergoing egg harvesting is often impractical in seriously ill 
patients. 
 
Older patients 
The burden of uveitis in older subjects is higher than previously appreciated. 
Interestingly, data from 3 studies of causes of uveitis in older patients indi-
cated the disease was most often idiopathic in etiology and that an infectious 
cause was more prominent in young patients[37-39]. Masquerade syndromes, 
such as intraocular lymphoma, are more common in older patients[40]. Co-
morbidities may contribute to severe uveitis in the elderly, including asso-
ciated autoimmune diseases, cardiovascular disease and diabetes. Older pa-
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tients are more susceptible to the effects of systemic therapy, particularly cor-
ticosteroid therapy, which may be associated with osteoporosis, diabetes, 
hypertension, muscle wasting and raised intraocular pressure. There have 
been no long-term studies of the effect immunosuppressive therapy in older 
patients and this represents an unmet need in this group of patients[41].  
 
The SITE Cohort Study, the MUST Trials, and several other publications have 
provided valuable information with regards to the safety and side effect profile 
of systemic immunosuppressive therapy in adult patients[6, 32, 35, 42-44]. 
The most commonly used corticosteroid sparing medications, such as azathi-
oprine, methotrexate, mycophenolate and cyclosporine, are associated with 
an “acceptable” side effect profile. In contrast, alkylating agents, such as cyc-
lophosphamide, have an “unacceptable side effect profile” when used for pro-
longed periods of time. The SITE and MUST studies also have provided valu-
able information with regards to the effectiveness of systemic immunosup-
pression including the surprisingly infrequent occurrence of significant side 
effects. The data indicates that these drugs are effective and safe for sup-
pressing ocular inflammation if used according to guidelines.  
 
The SITE study indicated a low or negligible risk of malignancy causing death 
in patients on long-term immunosuppression for inflammatory eye dis-
ease[35]. In contrast, a recent Australian study found an increased risk of skin 
and cervical cancer in patients on long-term immunosuppressive therapy and 
has implications for the pre-treatment evaluation of patients treated with long-
term immunosuppression[21]. The data with respect to biological agents, par-
ticularly TNF inhibitors, is promising thus far and these drugs do not seem to 
be associated with an increased risk of malignancy based on the rheumato-
logical literature[45]. All patients should be evaluated at baseline to assess 
their risk of exacerbating or developing a malignancy, particularly patients with 
a recent history of malignancy, such as females with breast cancer. The need 
for more information with regards to the long-term effects of immunosuppres-
sive therapy, although difficult, is needed and prospective studies, and regi-
stry studies to record the prevalence of complications, such as malignancy, 
should be pursued[29].  
 
 
Recommendation 5. 
Review of infection risk and immunization status should be made prior 
to commencing systemic immunosuppressive and/or biologic therapy. 
Established evidence-based international guidelines, such as the CDC 
guidelines, should be followed in assessing and managing immuniza-
tion in patients with IED treated with systemic immunosuppressive and 
biological therapy. 
 
Disease-specific guidelines for immunization and prevention of infections 
have not been developed for patients with IED and the expert panel recom-
mends that evidence-based guidelines developed by the Centre for Disease 
Control (CDC) (www.cdc.gov/vaccine/hcp/acip-recs.html) and Infectious Dis-
ease Society of America (IDSA) should be followed[46]. Several other expert 
groups, including the ACR, have developed guidelines for immunization of pa-
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tients before and during therapy with immunosuppressive and biologic therapy 
and these provide helpful information in the management of patients with IED. 
The principles outlined in the CDC guidelines are summarized in Table 6. In 
general, and if possible, patients should be vaccinated before commencing 
immunosuppressive therapy. However, this usually will involve waiting at least 
a month before being able to start immunosuppressive or biologic therapy af-
ter immunization with a live viral or bacterial vaccine and this is not usually 
possible in subjects with vision threatening disease. Initiation of immunosup-
pression should not be delayed to facilitate vaccination if immediate treatment 
is needed. VZV is of significant importance in patients on immunosuppressive 
therapy because of the potential severity of this infection. There have been no 
published studies of VZV vaccination in patients with IED treated with immu-
nosuppression. An expert panel of the ACR has endorsed the recommenda-
tion that VZV vaccination is safe in adults receiving less than 20 mg of predni-
sone per day or other low-level immunosuppression[47]. Varicella immuniza-
tion should be administered to patients with chronic inflammatory disorders 
who are aged ≥60 years or who are aged 50–59 years and varicella positive, 
prior to initiation of immunosuppression or being treated with low-dose immu-
nosuppression. Other live vaccines should not be administered to patients 
with severe IED on IS therapy (Table 6).  
Patients with chronic inflammatory disease (such as IED), who are being 
treated or about to be treated with immunosuppressive agents, should be en-
couraged to keep their immunization to influenza, pneumococcus, haemophi-
lus and HBV up to date. The Infectious Diseases Society of America (IDSA) 
recommends that inactivated vaccines, including influenza, should be admi-
nistered to these patients based on the CDC annual schedule[48].  
 
Any recommended vaccines should not be withheld because of concerns 
about exacerbation of chronic immune-mediated or inflammatory illness[48]. 
Prospective studies in children with inflammatory bowel disease (IBD) and 
uncontrolled studies in patients with chronic inflammatory rheumatic disease, 
treated with immunosuppressive therapy, indicate that such patients develop 
an adequate and protective immune response to influenza vaccine[49]. In 
adult patients with rheumatoid arthritis or SLE the immune response to in-
fluenza vaccine was reduced in subjects receiving azathioprine, infliximab and 
rituximab[50]. Patients were able to tolerate influenza vaccine without serious 
adverse effects and vaccination was not associated with disease exacerba-
tion. Similarly, in a few studies in which pneumococcal vaccine has been tried 
in patients with rheumatoid arthritis treated with anti-TNF therapy and metho-
trexate, a reduced immune response to the vaccine was detected[51]. Pa-
tients receiving rituximab also had a reduced immune response. Both groups 
of patients had similar responses to vaccination with tetanus toxoid. It would 
be anticipated that patients with severe IED on such therapy would show a 
similarly reduced response but such vaccines should not be withheld[51].  
 
 
Recommendation 6. 
Evidence-based data and recommendations from expert committees 
should be used in selecting appropriate systemic therapy for patients 
with IED and this should inform the pre-treatment assessment. 
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Extensive experience in the use of immunosuppressive drugs in the treatment 
of a variety of diseases, particularly systemic rheumatologic and autoim-
mune/auto-inflammatory diseases, has resulted in significant changes in the 
therapeutic approaches to severe inflammatory eye disorders. Expert panels 
have published guidelines for the use of immunosuppressive drugs and bio-
logicals in patients with ocular inflammatory disorders and these recommen-
dations represent a consensus amongst experienced physicians and oph-
thalmologists[8, 13]. The recommended therapeutic approach is to individual-
ize treatment for patients based on a number of parameters including: the 
specific ocular syndrome (e.g. Behcet’s disease, Birdshot retinopathy etc.), 
the severity of their eye disease (e.g. anterior or posterior, bilateral and unila-
teral), age of the patient, associated systemic inflammatory disease (e.g. in-
flammatory Bowel disease, sarcoidosis), systemic co-morbidities (e.g. di-
abetes, osteoporosis, renal disease, liver disease, hypertension and heart 
disease) and the patient’s life-style and general preference. Specific therapies 
necessitate specific pre-treatment assessment and monitoring as outlined in 
Table 4. 
 
Evidence based information should guide specific IS therapy in well-defined, 
non-infectious uveitis entities, such as Behcet’s disease, systemic vasculitis, 
sarcoidosis, Birdshot retinopathy and Vogt Koyanagi Disease (VKHD). Al-
though it would be useful to apply evidence-based medicine in the approach 
to immunosuppressive therapy for inflammatory eye disease, this is not al-
ways possible. There are only a few well-controlled, randomized, double-
masked trials comparing different immunosuppressive regimens in the treat-
ment of ocular inflammatory disorders[52]. 
 
 
Recommendation 7. 
Regular review, monitoring, patient education and preservation of quali-
ty of life are an essential component of therapy. 
 
Patients require review at frequent intervals during the early stages of treat-
ment to ensure that they are adequately immunosuppressed, the disease is 
responding appropriately and they do not manifest any side effects from the 
immunosuppressive treatment. The clinical response should be assessed and 
objective measures taken to ensure an adequate disease response is 
achieved. The lymphocyte count is maintained between 500-1000 cells/µl in 
patients on therapy that induces lymphopenia, such as azathioprine and cyc-
lophosphamide. Patients need to be monitored carefully for drug interactions 
during the course of their immunosuppressive therapy. Such drug interactions 
are common, particularly in the elderly [26](see Table 3).   
 
It is often difficult at the outset to establish a time frame for therapy.  There-
fore the overall aim should be to use the lowest dose of systemic corticostero-
ids for the shortest possible period of time. Steroid-sparing therapies should 
be employed with the aim of minimizing the potential for iatrogenic effects and 
maintain the IED in remission[13, 23]. A study by Kalinina and colleagues in-
dicated that in children with JIA and chronic uveitis a high number of patients 
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with inactive uveitis relapsed quickly after the withdrawal of MTX . They ob-
served that a longer period of inactivity (2 years) prior to withdrawal and a 
longer treatment period with methotrexate (3 years) reduced the chance of 
relapse after drug withdrawal[53]. 
 
It is imperative that the physician inform and educate the patient and family, 
as well as the patient’s primary care physician, with regard to the nature of the 
person’s disease, the aims of therapy and the potential for problems asso-
ciated with immunosuppressive therapy.   
 
Data from QoL studies in patients with uveitis are unfortunately limited, but 
point to the need for strategies to improve patients’ circumstances and to 
overcome the real and perceived problems associated with a chronic debilitat-
ing disease and the effects of systemic immunosuppression[54, 55]. 
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Table 1 
Summary of recommendations 
 
1. Prior to commencing long-term systemic immunosuppressive or biologic 
therapy, patients should have a comprehensive and individualized pre-
treatment evaluation (Table 2) to prevent or minimize therapy and dis-
ease-related complications. 
2. An extended consultative approach to management of patients with asso-
ciated systemic disease is recommended. 
 
3. Patients treated with high-dose and prolonged systemic corticosteroids (>3 
months) should have a baseline bone density and fracture risk assess-
ment, which should be repeated at regular intervals in patients on long term 
glucocorticoid therapy. Patients with evidence of significant bone loss 
and/or osteoporosis should have treatment to prevent further bone loss as 
early as possible after commencing corticosteroid therapy (Figure 1).  
 
4. Special considerations are essential in the pre-treatment assessment and 
management of children, pregnant women and older patients. 
 
5. Review of infection risk and immunization status should be made prior to 
commencing systemic therapy. Established evidence-based international 
guidelines, such as the CDC guidelines, should be followed in assessing 
and managing immunization in patients with IED being treated with sys-
temic immunosuppressive and biological therapy. 
 
6. Evidence-based data and recommendations from expert committees 
should be used in selecting appropriate systemic therapy for patients with 
IED and this should inform the pre-treatment assessment. 
 
7. Regular review, monitoring, patient education and preservation of quality 
of life are essential components of therapy. 
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Table 2 
Inflammatory eye disease pre-treatment assessment for patients requiring immuno-
suppressive treatment and or biologicals 
 
Clinical Relevant history and clinical as-
sessment 
Investigations, if indicated 
Infections to 
be excluded to 
prevent reacti-
vation or ex-
acerbation 
 
Hepatitis, sexually transmitted in-
fections (STI), dental disease, hu-
man papilloma virus cervical infec-
tion, past history of or exposure to 
tuberculosis (TB). 
HIV, HBV, HCV, VDRL, TB (Chest X-ray if 
clinically required), Skin tests or QantiFE-
RON-TB Gold test for TB. Pap smear and 
HPV examination.  
Hematology 
 
History of anemia, leukopenia, 
bleeding disorders and thrombosis. 
FBC/ESR/CRP. 
Anti-cardiolipin antibodies ACL) and β2-
microglobulin. 
Metabolic Renal, liver, endocrine or metabolic 
disease including obesity 
Blood sugar level (BSL), lipids, 
urea/creatinine, electrolytes, Liver Func-
tion Tests (LFT’s), urinalysis, uric acid. 
Thiopurine Methyltransferase (TPMT) test 
before use of azathioprine. 
Bone disease Age >60 years and post-
menopausal woman. 
Previous corticosteroid therapy. 
Osteopenia or fracture. 
Bone densitometry (DEXA scan). 
Calcium, vitamin D. 
Assess fracture risk. 
Vascular risk 
 
Hypertension, hyperlipidemia, di-
abetes, IHD, vascular disease. 
Blood pressure, lipids, BSL, C reactive 
protein (CRP). 
Doppler, if clinically indicated. 
Neoplasia Previous malignancy or present 
skin, cervical tumors, lymphoma 
Abnormal Pap smear (HPV). 
Examine skin, cervix, lymph nodes/spleen 
etc. 
Pap smear (HPV). 
 
Autoimmune 
(biologicals)  
 
Autoimmune disease features, par-
ticularly before use of biologics. 
Symptoms suggestive of demyeli-
nating illness 
ANA, ENA, DNA, ACL (B2 GPI), ANCA. 
Urine test for blood, casts and protein. 
Immunoglobulins and Immunoelectorpho-
resis. 
MRI brain- particularly in patients with in-
termediate uveitis.  
Medications Existing therapy, drug interactions, 
drug allergies and adverse reac-
tions. 
Check for interactions and allergy-IgE 
specific tests and skin tests only if aller-
gies are reported. 
Immunization 
/vaccination  
Immunization history, immune sta-
tus and need for pre-
immunosuppression vaccination. 
 
Serology tests for specific infections 
(HBV, VZV, pneumococcus). 
Special risk 
groups 
Children - drug dosages, immuniza-
tion and long-term effects. 
Pregnancy and planned pregnancy 
– contraception, lactation and tera-
togenicity risk. 
Elderly - co-morbidities, poly-
pharmacy and drug interactions. 
Growth charts for children. 
Check - drug dosage, interactions and 
teratogenicity. 
Pregnancy test - if appropriate. 
Fertility testing and sperm/ova storage - if 
indicated in treatment with alkylating 
agents. 
 
 
Abbreviations: HIV human immunodeficiency virus, HBV hepatitis B virus, 
HCV hepatitis C virus, TB Tuberculosis, HPV human papilloma virus, FBC full 
blood count, ANA antinuclear antibody, ANC anti-neutrophil cytoplasmic anti-
body, VZV Varicella zoster virus.
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Table 3 
Immunosuppressive Drugs for Inflammatory Eye Disease 
 
Class Generic 
Name 
Initial Dose Mechanism Onset 
of Ac-
tion 
Drug interactions Common Side Ef-
fects 
Investigations and 
monitoring 
        
Anti-
metabo-
lites 
Azathio-
prine 
1 mg/kg/day 
increasing to 
2-3 
mgm/Kg/day 
as a single or 
multiple dos-
es 
Alters purine 
metabolism 
and inhibits 
CD28 signal-
ing 
1-3 
months 
Mycophenolate 
Warfarin 
ACE inhibitors 
Co-trimoxazole 
Allopurinol 
Sulfasalazine 
Bone marrow sup-
pression (leukopenia, 
thrombocytopenia), 
Gl upset, hepatitis 
PNP deficiency 
Initial TMPT level 
FBC - baseline; 1, 2, 4 
then 8 weekly 
U/E/Cr and LFTs - 
baseline; 1, 2 then 4 
weekly   
 Methotrex-
ate 
10-25 mg/wk. 
Oral, subcu-
taneous or 
intra muscu-
lar injection 
Inhibits dihy-
drofolate re-
ductase 
2 weeks 
to 3 
months 
Alcohol, Antibiotics 
Cyclosporine 
NSAID 
Probenecid 
Sulfasalazine 
Co-trimoxazole 
Bone marrow sup-
pression, stomatitis, 
hair loss, nau-
sea/vomiting, Gl up-
set, hepatotoxicity 
(hepatitis, cirrhosis), 
pneumonitis, fetal 
loss 
FBC - baseline; 2, 4 
then 8 weekly 
U/E/Cr and LFTs -
baseline; 1, 2 then 4-8 
weekly   
 Mycophe-
nolate (-
mofetil or -
Na) Cell-
cept 
500 mg BID 
increasing to 
1gm BD 
IMP dehy-
drogenase 
inhibitor (pu-
rine synthe-
sis) 
2 weeks 
to 3 
months 
Azathioprine, antacids; sevelamer, 
Probenecid; PPIs; antibiotics (exclud-
ing co-trimoxazole) 
Diarrhea, nausea, 
neutropenia, infec-
tion 
FBC - baseline; 2, 4 
then 4-8 weekly 
U/E/Cr and LFTs - 
baseline, 2 then 4-8 
weekly   
        
T-cell 
inhibitors 
Cyclospo-
rine 
3- 
5mg/kg/day 
(divided 
dose) 
Inhibits calci-
neurin and 
thereby inhi-
bits NFAT 
and IL-2 syn-
thesis 
2-6 
weeks 
Anti-inflammatory drugs; antibiotics; 
anticonvulsants 
sirolimus; diuretics; erythropoietin; 
HMG-CoA reductase inhibitors, sta-
tins; nephrotoxic drugs- including- 
tacrolimus, NSAIDs, methotrexate, 
vancomycin, aminoglycosides am-
photericin B, ciprofloxacin, melpha-
lan, trimethoprim (+ sulfamethox-
azole), colchicine; Ca-channel block-
Renal dysfunction, 
tremor, hirsutism, 
hypertension, gum 
hyperplasia 
FBC - baseline; 2, 4 
then 8 weekly 
U/E/Cr and LFTs -
baseline; 1, 2 then 4-8 
weekly   
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ers; grapefruit juice; corticosteroids; 
digoxin; etoposide; repaglinide; ma-
crolides; azole antifungals; amioda-
rone; allopurinol; sulfadimidine; he-
patic enzyme inducers; CYP3A4 in-
hibitors (i.e. carbamazepine, St 
John's wort) 
 Tacrolimus 0.15mg/kg/b
d 
Increasing to 
2-3 mgm bd 
Inhibits calci-
neurin and 
thereby inhi-
bits NFAT 
and IL-2 syn-
thesis 
2-6 
weeks 
Similar to cyclosporine 
aminoglycosides, gyrase inhibitors; 
potassium sparing diuretics e.g., ami-
loride, spironolactone, triamterene 
sirolimus; Ca channel blockers 
CYP3A4 inducers (e.g. carbamaze-
pine, St John's wort) contraceptives; 
NSAIDs; highly protein bound drugs 
(e.g. oral anticoagulants), CYP3A4 
inhibitors, e.g. grapefruit juice anti-
fungals (e.g. ketoconazole), HIV pro-
tease inhibitors clarithromycin, clo-
trimazole, erythromycin, omeprazole  
Nephrotoxicity, high 
BP, neurotoxicity, 
hyperkalemia, hypo-
magnesaemia, hepa-
titis, diabetes, tre-
mor. 
FBC - baseline; 1, 2, 4 
then 8 weekly 
U/E/Cr and LFTs - 
baseline; 1, 2 then 4 
weekly   
        
Alkylating 
agents 
Cyclophos-
phamide 
1-2 
mg/kg/day as 
oral medica-
tion.  
Can also be 
used as IV 
pulse thera-
py. 
Cross links 
DNA and 
interferes 
with replica-
tion and cell 
division 
2-8 
weeks 
Inducers of liver enzyme such as 
phenobarbitone, imipramine, pheno-
thiazines, hypoglycemics; phenytoin; 
benzodiazepines; cytotoxics, immu-
nosuppressants; digoxin; Mesna; 
corticosteroids; anticoagulants; live 
vaccines; alcohol; grapefruit juice; 
Bone marrow sup-
pression, infection, 
hematuria and he-
morrhagic cystitis, 
increased risk of ma-
lignancy, sterility, 
alopecia 
FBC - baseline; 1, 2, 4 
then 8 weekly 
U/E/Cr and LFTs - 
baseline; 1, 2 then 4-8 
weekly   
 Chloram-
bucil 
0.1 
mg/kg/day 
Cross links 
DNA and 
interferes 
with replica-
tion and cell 
division 
4-12 
weeks 
Phenylbutazone; epileptogenic 
drugs; live vaccines; purine nucleo-
side analogues 
Bone marrow sup-
pression, infection, 
increased risk malig-
nancy, sterility 
FBC - baseline; 1, 2, 4 
then 8 weekly 
U/E/Cr and LFTs - 
baseline; 1, 2 then 4-8 
weekly   
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Table 4 
Biologics and Inflammatory Eye Disease 
Class Generic 
Name 
Initial Dose Mechanism Onset of 
Action 
Common Side Effects Investigations 
       
TNF Block-
ers 
Infliximab 5 mg/kg/ IV  
over 2 hrs, at 
0, 2 and 6 
weeks 
Binds soluble and 
membrane-bound 
TNFα 
10 weeks Injection site and infusion reactions, 
bacterial infections, reactivation of TB, 
headache, demyelination, rash, abdo-
minal pain, diarrhea, respiratory infec-
tions, ANA and DNA antibodies. 
FBC - baseline; 4 then 8 
weekly 
U/E/Cr and LFTs - baseline; 
2 then 8-12 weekly   
 
 Adalimumab 40 mg/2wks 
SC 
Binds soluble and 
membrane-bound 
TNFα 
2-16 weeks Injection site reactions, bacterial infec-
tions, reactivation of TB, headache, 
rash, abdominal pain, demyelination, 
diarrhea, respiratory infections, ANA 
and DNA antibodies. 
FBC - baseline; 4 then 8 
weekly 
U/E/Cr and LFTs - baseline; 
2 then 8 weekly   
 Etanercept 50 mg week-
ly 
 P75 TNF receptor 
fusion protein biva-
lent binding of TNF 
4-8 weeks Injection site and infusion reactions, 
bacterial infections, reactivation of TB, 
headache, demyelination, rash, abdo-
minal pain, diarrhea, respiratory infec-
tions, ANA and DNA antibodies. 
May induce uveitis. 
FBC - baseline; 4, then 8 
weekly 
U/E/Cr and LFTs - baseline; 
4 then 8 weekly   
       
Interferons Interferon-
α2b 
3-6 million 
IU/day SC  
1-3 times per 
week 
Promotes Treg de-
velopment 
up regulates TGF-β, 
IL-1R antagonist, 
soluble TNFR 
2-4 weeks Injection site reactions, flu-like symp-
toms, depression and suicidal ideation. 
Leucopenia and abnormal liver func-
tion tests. Thyroid and SLE autoanti-
bodies. 
FBC - baseline; 4 then 8 
weekly 
U/E/Cr and LFTs - baseline; 
2 then 8 weekly   
 Interferon-
α2a 
3-6 million 
IU/day SC  
1-3 times per 
week 
Promotes Treg de-
velopment 
up regulates TGF-β, 
IL-1R antagonist 
2-4 weeks Injection site reactions, flu-like symp-
toms, depression and suicidal ideation. 
Leucopenia and abnormal liver func-
tion tests . Thyroid and SLE autoanti-
bodies. 
FBC - baseline; 4 then 8 
weekly 
U/E/Cr and LFTs - baseline; 
2 then 8 weekly   
       
IL-1R Block-
er 
Anakinra 1 mg/kg/day 
SC 
Competitively inhibits 
IL-1 binding to IL-1R 
4 weeks Injection site reactions, decreases in 
neutrophil count, increased infections 
FBC - baseline; 4 then 8 
weekly 
U/E/Cr and LFTs - baseline; 
2 then 8 weekly   
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
 18 
 Canakinu-
mab 
Adults >40kg 
150 mg S/c 
8-weekly 
Competitively inhibits 
IL-1 binding to IL-1β 
4 weeks Injection site reactions, decreases in 
neutrophil count, increased infections, 
headache, vertigo, weight gain, nau-
sea, diarrhea, myalgia, pharyngitis 
FBC - baseline; 4 weeks then 
8 weekly 
U/E/Cr and LFTs - baseline; 
2 then 8 weekly   
       
IL-6 Blocker Tocilizumab 4-8 mg/Kg 
every 4 
weeks 
Competitive inhibitor 
of IL-6 receptor 
4 weeks Increased cholesterol, ALT, AST, 
headache, vertigo, hypertension, infec-
tions, diverticulitis and gut perforation. 
FBC - baseline; 4 weeks then 
8 weekly 
U/E/Cr and LFTs - baseline; 
2 then 8 weekly   
       
CD20 Block-
er 
Rituximab 375 mg/m2 
IV 0, 2 weeks 
and then as 
required 
Binds to the CD20 
antigen on B cells 
3-4 months Infusion reactions, infections, cytope-
nias. Delay up to 3-4 months in onset 
of action. 
FBC and T & B cells - base-
line; 4 then 8 weekly 
U/E/Cr/Immunoglobulins and 
LFTs - baseline; 4 then 8 
weekly   
       
Plasma 
Product 
Intravenous 
immunoglo-
bulin 
(IVIG) 
400 
mg/kg/day 
for 5 days 
and then 
monthly 
Suppresses T and B 
cell responses 
4-8 weeks Infusion reactions, delayed infusion 
reactions, headache. Anaphylaxis par-
ticularly in patients with anti-IgA anti-
bodies. 
FBC - baseline; 4 then 8 
weekly 
U/E/Cr and LFTs -baseline; 
then 8 weekly   
 
TNF = Tumor necrosis factor, Treg = Regulatory T cell, IL-1R = Interleukin-1 receptor, TNFR = Tumor necrosis factor receptor, BID = twice daily; BP = blood 
pressure; Gl = gastrointestinal; IM = intramuscular; IV = intravenous; LFTs = liver function tests; PO = orally; Q = every; SC = subcutaneously; U/E/Cr = urine, 
electrolytes, creatinine, FBC= Full Blood Count. 
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Table 5 
ACR recommendations for life style modification and assessment of patients starting  systemic glucocorticoids[30] 
 
Smoking cessation 
Decreased alcohol intake (<2 standard drinks/day) 
Weight bearing exercises should be encouraged 
Calcium and vitamin D measurement and intake 
Baseline dual x-ray absorptiometry 
Fall risk assessment especially in older subjects 
Baseline height measurement 
Assessment of prevalent fragility fractures 
Spinal radiology for patients on >5 mg of prednisone or equivalent 
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Table 6 
Vaccination of patients with IED on immunosuppressive medications based on CDC guidelines* 
 
Vaccine Prior to starting  
immunosuppression  
(>1 month) 
Low-level immunosuppression 
patients receiving: 
prednisone <2mg/kg/day 
methotrexate <0.4 mg/kg/week 
azathioprine <3 mg/kg/day 
High-level 
immunosuppression 
patients receiving: 
greater than low-level criteria or 
TNF inhibitors or rituximab 
Influenza (inacti-
vated) 
Usual immunization regi-
men 
Usual Usual 
Hepatitis A Usual Usual Usual 
Hepatitis B Usual Usual Usual 
DPT Usual Usual Usual 
HPV Usual Usual Usual 
H. Influenza Usual Usual Usual 
Meningococcal con-
jugate 
Usual Usual Usual 
Pneumococcal 
PCV13 
Recommended >6 yrs. of 
age   
Recommended >6 years of 
age 
Recommended >6years of age 
Pneumococcal 
PPSV23 
Recommended ≥2 yrs. of 
age 
Recommended ≥2 years of 
age 
Recommended ≥2 years of age 
Polio (inactivated) Usual Usual Usual 
Rotavirus- live Usual Contraindicated Contraindicated 
Varicella- live Usual Contraindicated Contraindicated 
MMR-live Usual Contraindicated Contraindicated 
    
 
* www.cdc.gov/vaccine/hcp/acip-recs.html 
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